Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 4/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PKLR | P30613 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745433 | 0.84 | KDM4E (0.37) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 | |
| SCHEMBL20745408 | 0.82 | KDM4E (0.33) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 | |
| SCHEMBL20761543 | 0.81 | SMN1; SMN2 (0.35) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 | |
| SCHEMBL20745450 | 0.81 | KDM4E (0.33) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 | |
| SCHEMBL20761690 | 0.80 | KDM4E (0.34) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 | |
| SCHEMBL20745467 | 0.80 | ALDH1A1 (0.33) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 | |
| SCHEMBL20745443 | 0.80 | KDM4E (0.32) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 | |
| SCHEMBL20745501 | 0.80 | KDM4E (0.34) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 | |
| SCHEMBL20745426 | 0.79 | HSD17B10 (0.32) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 | |
| SCHEMBL30514174 | 0.79 | KDM4E (0.34) | KDM4EHSD17B10TDP1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117186119-A | Pyruvate kinase activators for the treatment of hematological disorders | 安吉奥斯医药品有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-111032046-B | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-111032045-B | Pyruvate kinase activators for the treatment of hematological disorders | 安吉奥斯医药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230226055-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226055-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3668512-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668513-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-111032046-A | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2020-04-17 | — | — | CN | disclosed |
| CN-111032045-A | Pyruvate kinase activators for the treatment of blood disorders | 安吉奥斯医药品有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019035864-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035863-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | KDM4E 692/4885HSD17B10 767/4885TDP1 1491/4885 |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | PDK1, PDK2, PDK4 | KDM4E 692/4885HSD17B10 767/4885TDP1 1491/4885 |
| US-20230226055-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | KDM4E 1481/4885HSD17B10 1064/4885TDP1 830/4885 |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | KDM4E 1481/4885HSD17B10 1064/4885TDP1 830/4885 |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | KDM4E 1481/4885HSD17B10 1064/4885TDP1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.